Salubris Biotherapeutics to Speak at ACCESS CHINA BD Forum @ BIO

June 15, 2025 (Boston) — We are glad to announce that Samuel Murphy, the CEO of Salubris Biotherapeutics, will be presenting at the ACCESS CHINA BD Forum @BIO on June 15, 2025. ACCESS CHINA Biotech Forum is the largest corporate access event between Asia and the western biopharma industry.

About Salubris Biotherapeutics

SalubrisBio is a US-based clinical-stage biotechnology company dedicated to discovering and developing complex biologics for cardiovascular disease and cancer. SalubrisBio is currently developing JK07, a novel antibody fusion in an ongoing global Phase 2 study for the treatment of heart failure, and JK06, a quadrivalent, biparatopic ADC targeting 5T4. Multiple preclinical programs in cardiovascular disease and cancer are advancing towards the clinic.

About the speaker

Sam is currently CEO of SalubrisBio and has worked at SalubrisBio since 2017. Prior to joining SalubrisBio, Sam worked for more than ten years in strategy consulting and transaction advisory services across several global firms, most recently as a Senior Principal at IMS (now IQVIA). Sam completed his PhD in Virology at the University of Pennsylvania and his Post-Doctoral Fellowship in Gene Therapy and Translational Medicine at Children’s Hospital of Philadelphia. Sam has served on the board of directors for public and private biotech companies.

About ACCESS CHINA BD Forum @BIO

‘ACCESS CHINA BD Forum @BIO is scheduled to be held on June 15, 2025, at Seaport Boston Hotel. This year’s ACCESS CHINA BD Forum @BIO will convene 80 distinguished guests for an afternoon of strategic networking, business development, and thought leadership, with a special emphasis on China’s dynamic biotechnology landscape and global collaboration opportunities.

Conference Name: ACCESS CHINA BD Forum @BIO

Date: June 15, 2025

Content: Keynote Speeches, Panel Discussion, 10 Elevator Pitch, and Closed-Door Dinner Reception.

Participants: Pharma/Biotech senior management and BD’s

View more information at https://biotochina.org/